Please assess the completion status of the following clinical trial:

Trial Title: Therapy for Chronic Cold Agglutinin Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. CAD diagnosis defined by the combination of:~   * Chronic haemolysis~  * Cold agglutinin titre \> 64~  * Positive direct antiglobulin test when performed with polyspecific antiserum, negative (or only weakly positive) with anti-IgG, and strongly positive with anti-C3d~2. The presence of a clonal B-cell lymphoproliferative disorder defined by:~   * Monoclonal IgMκ band by serum electrophoresis and immunofixation, and~  * Lymphocyte phenotype with κ/λ-ratio \> 3.5 and CD20+,κ+ co-expression, using flowcytometric immunophenotyping of bone marrow aspirates~3. Clinical symptoms requiring treatment, such as anaemia or Raynaud-like symptoms~4. Informed consent~Exclusion Criteria:~1. An aggressive lymphoma~2. Blood lymphocyte count \> 50 . 109/L~3. Non-lymphatic malignant disease other than basal cell carcinoma~4. Contra-indications to rituximab or fludarabine therapy~5. Inability to cooperate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).